U.S., Oct. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07881432) titled 'A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes' on Oct. 12.
Brief Summary: The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: eloralintide and tirzepatide
Administered SC
DRUG: Eloralintide
Administered SC
DRUG: Tirzepatide
Administered SC
DRUG: Placebo
Administere...